Publications by authors named "Pritesh N Bodalia"
Unlabelled: Aims To assess the transfer of patients treated with originator biological therapies to biosimilar products in a large UK tertiary referral hospital reflecting practice within the National Health Service (NHS) using prospectively collected data by a hospital-based registry administered by the Biologics Steering Group (BSG).
Methods: We analysed data collected prospectively in a hospital-based registry in a large NHS tertiary referral hospital in the UK. The registry was administered by the hospital's BSG, which considered requests for patients to remain on or revert to originator products.
Determine the optimal, licensed, first-line anticoagulant for prevention of ischemic stroke in patients with non-valvular atrial fibrillation (AF) in England and Wales from the UK National Health Service (NHS) perspective and estimate value to decision making of further research. We developed a cost-effectiveness model to compare warfarin (international normalized ratio target range 2-3) with directly acting (or non-vitamin K antagonist) oral anticoagulants (DOACs) apixaban 5 mg, dabigatran 150 mg, edoxaban 60 mg, and rivaroxaban 20 mg, over 30 years post treatment initiation. In addition to death, the 17-state Markov model included the events stroke, bleed, myocardial infarction, and intracranial hemorrhage.
View Article and Find Full Text PDFTo compare the efficacy, safety, and cost effectiveness of direct acting oral anticoagulants (DOACs) for patients with atrial fibrillation. Systematic review, network meta-analysis, and cost effectiveness analysis. Medline, PreMedline, Embase, and The Cochrane Library.
View Article and Find Full Text PDFArticle Synopsis
- - Warfarin is commonly used for stroke prevention in atrial fibrillation (AF) and for treating venous thromboembolism (VTE), but its use is often limited due to the risk of bleeding and the costs associated with monitoring therapy.
- - The study aimed to identify the most effective oral anticoagulants for stroke prevention in AF as well as for the prevention and treatment of VTE through systematic reviews and cost-effectiveness analyses.
- - The research focused on comparing novel oral anticoagulants (NOACs), warfarin, and low-molecular-weight heparin (LMWH), evaluating outcomes such as stroke incidence, VTE occurrence, bleeding complications, and overall cost-effectiveness.
Aims: To evaluate the comparative efficacy (50% reduction in seizure frequency) and tolerability (premature withdrawal due to adverse events) of anti-epileptic drugs (AEDs) for refractory epilepsy.
Methods: We searched Cochrane Central Register of Controlled Trials (Cochrane Library 2009, issue 2) including Epilepsy Group's specialized register, MEDLINE (1950 to March 2009), EMBASE (1980 to March 2009), and Current Contents Connect (1998 to March 2009) to conduct a systematic review of published studies, developed a treatment network and undertook a network meta-analysis.
Results: Forty-three eligible trials with 6346 patients and 12 interventions, including placebo, contributed to the analysis.